Literature DB >> 15291681

Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list-controlled open trial.

David F Tolin1, Nicholas Maltby, Gretchen J Diefenbach, Scott E Hannan, Patrick Worhunsky.   

Abstract

BACKGROUND: Cognitive-behavioral therapy (CBT) is generally recommended for obsessive-compulsive disorder (OCD) patients who have failed to respond to approved medications. However, few studies of the efficacy of CBT have selected patients who did not respond to medications.
METHOD: We selected 20 adult OCD (DSM-IV criteria) patients with a history of inadequate response to adequate doses of multiple medications, as well as a high rate of comorbid disorders. After a 1-month wait-list period, patients received 15 sessions of outpatient CBT incorporating exposure and ritual prevention.
RESULTS: OCD severity (as measured with the Yale-Brown Obsessive Compulsive Scale) decreased significantly (p <.05) after treatment, and gains appeared to have been maintained over a 6-month follow-up period. Analysis of clinical significance indicated that 53% (8/15) of treatment completers met this criterion at posttreatment and 40% (6/15) met the criterion at 6-month follow-up. The sample was characterized as having generally poor insight and putting low effort into CBT; these factors significantly (p <.05) predicted degree of improvement.
CONCLUSION: CBT is a useful treatment for OCD patients who have failed to respond adequately to multiple serotonin reuptake inhibitor medications. However, these results were attenuated compared with previous trials. Patients with a long history of poor response to medication may have poor insight and/or not put sufficient effort into treatment; these factors are likely to diminish treatment outcome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15291681     DOI: 10.4088/jcp.v65n0708

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  29 in total

1.  Understudied clinical dimensions in pediatric obsessive compulsive disorder.

Authors:  Adam B Lewin; Nicole Caporino; Tanya K Murphy; Gary R Geffken; Eric A Storch
Journal:  Child Psychiatry Hum Dev       Date:  2010-12

2.  Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Authors:  Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Jonathan D Huppert; Shawn Cahill; Michael J Maher; Carmen P McLean; James Bender; Sue M Marcus; Monnica T Williams; Jamie Weaver; Donna Vermes; Page E Van Meter; Carolyn I Rodriguez; Mark Powers; Anthony Pinto; Patricia Imms; Chang-Gyu Hahn; Raphael Campeas
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

3.  Avoidance, Insight, Impairment Recognition Concordance, and Cognitive-Behavioral Therapy Outcomes in Pediatric Obsessive-Compulsive Disorder.

Authors:  Robert R Selles; Davið R M A Højgaard; Tord Ivarsson; Per Hove Thomsen; Nicole Michelle McBride; Eric A Storch; Daniel Geller; Sabine Wilhelm; Lara J Farrell; Allison M Waters; Sharna Mathieu; S Evelyn Stewart
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2019-06-20       Impact factor: 8.829

4.  Intensive Family-Based Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder: Applications for Treatment of Medication Partial- or Nonresponders.

Authors:  Wendi E Marien; Eric A Storch; Gary R Geffken; Tanya K Murphy
Journal:  Cogn Behav Pract       Date:  2009-08

5.  Insight and alexithymia in adult outpatients with obsessive-compulsive disorder.

Authors:  Domenico De Berardis; Daniela Campanella; Francesco Gambi; Gianna Sepede; Gabriele Salini; Alessandro Carano; Raffaella La Rovere; Lucia Pelusi; Laura Penna; Alessandra Cicconetti; Carla Cotellessa; Rosa Maria Salerno; Filippo Maria Ferro
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-02-21       Impact factor: 5.270

Review 6.  Psychotherapy for obsessive-compulsive disorder.

Authors:  Eric A Storch; Amy Mariaskin; Tanya K Murphy
Journal:  Curr Psychiatry Rep       Date:  2009-08       Impact factor: 5.285

7.  Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?

Authors:  Michael G Wheaton; David Rosenfield; Edna B Foa; H Blair Simpson
Journal:  J Consult Clin Psychol       Date:  2015-05-25

Review 8.  New modalities of assessment and treatment planning in depression: the sequential approach.

Authors:  Giovanni A Fava; Elena Tomba
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

9.  Behavioral avoidance predicts treatment outcome with exposure and response prevention for obsessive-compulsive disorder.

Authors:  Michael G Wheaton; Marina Gershkovich; Thea Gallagher; Edna B Foa; H Blair Simpson
Journal:  Depress Anxiety       Date:  2018-02-02       Impact factor: 6.505

10.  Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.

Authors:  Carmen P McLean; Laurie J Zandberg; Page E Van Meter; Joseph K Carpenter; Helen Blair Simpson; Edna B Foa
Journal:  J Clin Psychiatry       Date:  2015-12       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.